Literature DB >> 32962759

A nosocomial cluster of vancomycin resistant enterococci among COVID-19 patients in an intensive care unit.

Stefanie Kampmeier1, Hauke Tönnies2, Carlos L Correa-Martinez2, Alexander Mellmann2, Vera Schwierzeck2.   

Abstract

BACKGROUND: Currently, hospitals have been forced to divert substantial resources to cope with the ongoing coronavirus disease 2019 (COVID-19) pandemic. It is unclear if this situation will affect long-standing infection prevention practices and impact on healthcare associated infections. Here, we report a nosocomial cluster of vancomycin-resistant enterococci (VRE) that occurred on a COVID-19 dedicated intensive care unit (ICU) despite intensified contact precautions during the current pandemic. Whole genome sequence-based typing (WGS) was used to investigate genetic relatedness of VRE isolates collected from COVID-19 and non-COVID-19 patients during the outbreak and to compare them to environmental VRE samples.
METHODS: Five VRE isolated from patients (three clinical and two screening samples) as well as 11 VRE and six vancomycin susceptible Enterococcus faecium (E. faecium) samples from environmental sites underwent WGS during the outbreak investigation. Isolate relatedness was determined using core genome multilocus sequence typing (cgMLST).
RESULTS: WGS revealed two genotypic distinct VRE clusters with genetically closely related patient and environmental isolates. The cluster was terminated by enhanced infection control bundle strategies.
CONCLUSIONS: Our results illustrate the importance of continued adherence to infection prevention and control measures during the COVID-19 pandemic to prevent VRE transmission and healthcare associated infections.

Entities:  

Keywords:  COVID-19; Healthcare-associated infection; Intensive care unit; Nosocomial VRE cluster; Surface contamination; vanB

Mesh:

Year:  2020        PMID: 32962759      PMCID: PMC7506805          DOI: 10.1186/s13756-020-00820-8

Source DB:  PubMed          Journal:  Antimicrob Resist Infect Control        ISSN: 2047-2994            Impact factor:   4.887


Introduction

In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was discovered in Wuhan City, China and rapidly developed into a pandemic that poses a serious threat to health care systems worldwide [1-3]. It soon became apparent that even in developed countries COVID-19 will set an unprecedented challenge to hospitals due to a high influx of critically ill patients, demand for mechanical ventilation beds and shortage of personal protective equipment (PPE) [4-6]. Understandably, major staff and financial resources have been diverted to COVID-19 outbreak management in hospitals, especially in regions with high case numbers [7]. One concern among the infection prevention community is that the COVID-19 pandemic will cause “collateral damage” to long-established infection control measures including the prevention of healthcare-associated infections [8]. So far, it remains unknown if the present diversion of hospital resources and changes in infection control practices will translate into an increase of nosocomial transmissions, in particular of multidrug resistant organisms (MDRO), during the COVID-19 pandemic or if the increased efforts to improve infection control measures will have a positive effect on nosocomial MDRO transmissions [9, 10]. In recent years, the incidence of VRE infections has increased worldwide, including in Germany [11]. VRE infections are associated with significant mortality, in particular in patients with multiple co-morbidities and ICU patients [12, 13]. Nosocomial transmission of VRE is frequent, partly because enterococci are resilient and survive for prolonged periods on inanimate surfaces i.e. medical equipment, work top surfaces, furniture [14, 15]. Here, we describe a nosocomial cluster of VRE that involved three COVID-19 patients as well as two SARS-CoV-2 negative ICU patients.

Methods

Clinical setting and infection control measures

The University Hospital Münster (UKM) is a 1800-bed care centre admitting ca. Seventy-four thousand patients per year and treating up to 140 patients on 11 ICUs or intermediate care units. During the COVID-19 pandemic, one of the ICUs was separated into two subunits, treating COVID-19 patients and non-COVID-19 patients, respectively. Enhanced infection control measures were put in place for confirmed and suspected COVID-19 patients, including isolation in the COVID-19 ward and the use of PPE (gloves, gowns, FFP2 masks and safety googles). In April 2020, VRE from clinically relevant samples (blood culture samples and pleural drainage) were detected in three patients from both ICU subunits. As this rate exceeded the baseline of three VRE infections per year on this ward, an outbreak investigation was initiated and – in accordance to the German guideline published in 2018 - a bundle strategy for terminating VRE transmission was implemented [16]. This bundle comprised a point prevalence screening among all patients, a VRE screening on admission and once a week for every patient, environmental sampling to detect VRE contamination of patient surroundings, contact precautions including the use of PPE (gloves and gowns) and patient isolation. Isolation of patients could be discontinued if three anorectal swab samples collected in at least a one-week interval without administering antibiotic therapy during this time were negative for VRE. In addition, intensified surface disinfection was established using an alkylamine, Incidin™ plus 0.5% (ECOLAB Healthcare, Monheim am Rhein, Germany), focussing in particular on patient rooms, nurses’ rooming homes, storage rooms and staff rest rooms. Moreover, hand hygiene training was performed among nurses, physicians and cleaning personnel.

Environmental sampling and testing method

Environmental sampling was performed using sterile packaged polywipes (mwe, Corsham, Wiltshire, UK) on contact surfaces and incubating them in Tryptic Soy Broth + lecithin tween (LT) (Merck Millipore, Eppelheim, Germany) for 24 h at 37 °C. Ten μL of this broth were streaked onto blood agar and VRE selective agar and incubated for 24 h at 37 °C. Suspected colonies were subcultured on blood agar and species identification was performed by MALDI-TOF-MS (Bruker Corporation, Bremen, Germany). Susceptibility testing for vancomycin was performed using Etest® (Bestbion GmbH, Liofilchem, Italy). Susceptibility testing for methicillin was performed using Cefoxitin antimicrobial susceptibility disks (Oxoid, ThermoFisher Scientific,Waltham, USA). Results wereevaluated in accordance with the EUCAST standards for clinical breakpoints (version 10.0).

Whole genome sequence-based typing

Confirmed E. faecium isolates were subjected to WGS using the Illumina MiSeq platform (Illumina Inc., San Diego, USA). Specifically, DNA was extracted using a glass-bead-based method [17] and 1 ng DNA was introduced into library preparation with a Nextera XT DNA sample preparation kit (Illumina) and paired-end sequenced with a MiSeq Reagent kit v2 250 bp (Illumina) with an average insertion size of 300 bp. Libraries were scaled to reach 100-fold sequencing coverage for an average genome size of 3 MB. Only sequencing runs that fulfilled the manufacturers’ specifications (Illumina) with respect to cluster density and Q30 were further analyzed. After sequencing, the raw reads were quality-trimming and de novo assembled using the SKESA algorithm with default parameters [18] that is implemented in the Ridom SeqSphere+ software version 7.0.1 (Ridom GmbH, Münster, Germany) [19]. For subsequent core genome multilocus sequence typing (cgMLST), the previously published cgMLST scheme for E. faecium was used [20]. Here, every sample had to have ≥95% extracted cgMLST targets, otherwise sequencing had to be repeated. Based on the allelic profiles from cgMLST; we constructed a minimum spanning tree to display the genetic relationships between isolates, a minimum spanning tree algorithm was applied. We rated isolates differing ≤3 alleles as closely related with a high likelihood of resulting from a clonal transmission event [21, 22]. In addition, van-genotypes and MLST sequence types (ST) were extracted from the WGS data in silico using SeqSphere+.

Results

Outbreak management and environmental sampling

After VRE has been detected in clinical samples from three patients from both ICU subunits in April 2020, patient screening for VRE was initiated as part of an outbreak investigation. Patient screening revealed two additional VRE positive patients (Fig. 1). Environmental sampling on relevant hand contact surfaces (e.g. nursing workspace, PC, monitor, infusion stand etc., n = 30) resulted in 17 swab sampling probes that were positive for E. faecium, of which 11 were VRE. Moreover, in 18 samples other nosocomial pathogens such as S. aureus (methicillin susceptible) (n = 6), E. faecalis (n = 6), Enterobacterales (n = 3) and nonfermenters (n = 3) were identified.
Fig. 1

Timeline of the nosocomial VRE cluster. VRE positive patients are illustrated chronologically. Each line represents the timeline of a single patient. Grey shading of lines indicates duration of residence on ICU. VRE isolates derived from clinical (red) or screening samples (black) are shown as dots within the lines

Timeline of the nosocomial VRE cluster. VRE positive patients are illustrated chronologically. Each line represents the timeline of a single patient. Grey shading of lines indicates duration of residence on ICU. VRE isolates derived from clinical (red) or screening samples (black) are shown as dots within the lines After establishing the previously mentioned infection control bundle strategy the cluster could be terminated immediately. No further VRE infections or nosocomial colonisations with this clone occurred to date, 5 months after the outbreak. All five patient samples, 11 environmental VRE and – for comparison – also the six susceptible environmental E. faecium isolates were subjected to WGS. The mean sequencing coverage was 133x (53-200x), the number of contigs ranged from 140 to 483 (mean = 243), the mean assembly size was 2.955,382 bp (range, 2.630,395–3.019,336 bp), and on average 98.6% (95.2–99.2%) of the 1423 cgMLST targets were detected. The analysis resulted in two clusters of five and nine closely related strains (≤ 3 alleles differing between genotypes) and eight singletons. Cluster 1 (C1) and cluster 2 (C2) are distantly related to each other (6 alleles differing between most similar genotypes). Both clusters C1 (P1, P2, E2, E6, E8) and C2 (P3, P4, P5, E1, E7, E9, E11, E12, E13) comprise patient and environmental isolates (Fig. 2). Interestingly, the VRE samples of the two SARS-CoV-2 negative patients are part of C1 while all samples collected from COVID-19 patients were C2. All samples of C1 and C2 were identified as ST117 and vanB. In all 16 VRE detected during the outbreak vanB could be detected. Most prevalent MLST ST was ST117 in 18 (81.8%) strains, of which 16 were tested vancomycin resistant and two vancomycin susceptible. Additional information of distribution of van-genes and MLST ST in patient and environmental isolates is displayed in Table 1.
Fig. 2

Minimum spanning tree of detected E. faecium. Minimum spanning tree of 17 environmental (E) and five patient (P) vancomycin resistant (red) and vancomycin susceptible (blue) isolates illustrating their genotypic relationship based on up to 1423 cgMLST target genes, pairwise ignore missing values. Every circle represents one genotype, the size of circles correlates with the number of identical genotypes. Grey colouring indicates close genetic relation (≤ 3 alleles differing between two genotypes)

Table 1

E. faecium isolates derived from patients (P) and environmental sites (E)

Isolate no.MLST STVan-genotypeOrigin of sample or sampling location
P1ST117vanBblood culture
P2ST117vanBpleural drainage fluid
P3ST117vanBblood culture
P4ST117vanBscreening sample
P5ST117vanBscreening sample
E1ST117vanBnon-isolation ward, room 9
E2ST117vanBnon-isolation ward, room 9 (anteroom)
E3ST117non-isolation ward, hallway (furniture)
E4ST117non-isolation ward, clean utility room (designated iv preparation station)
E5ST117vanBholding area (furniture)
E6ST117vanBnon-isolation ward, office space (work surfaces)
E7ST117vanBCOVID-19 isolation ward, window
E8ST117vanBCOVID-19 isolation ward, PC
E9ST117vanBCOVID-19 isolation ward, intermediate life support ward emergency bag
E10ST80COVID-19 isolation ward, intermediate life support ward emergency bag
E11ST117vanBCOVID-19 isolation ward, anteroom
E12ST117vanBCOVID-19 isolation ward, anteroom (clean)
E13ST117vanBCOVID-19 isolation ward, clean utility room
E14ST324COVID-19 isolation ward, clean utility room
E15ST117vanBCOVID-19 isolation ward, nurses’ station (furniture)
E16ST107COVID-19 isolation ward, nurses’ station (PC)
E17ST361COVID-19 isolation ward, office space (work surfaces)
Minimum spanning tree of detected E. faecium. Minimum spanning tree of 17 environmental (E) and five patient (P) vancomycin resistant (red) and vancomycin susceptible (blue) isolates illustrating their genotypic relationship based on up to 1423 cgMLST target genes, pairwise ignore missing values. Every circle represents one genotype, the size of circles correlates with the number of identical genotypes. Grey colouring indicates close genetic relation (≤ 3 alleles differing between two genotypes) E. faecium isolates derived from patients (P) and environmental sites (E)

Discussion

In the present study, we demonstrated the transmission of VRE in an ICU by WGS during the ongoing COVID-19 pandemic. The close genetic relatedness between environmental VRE samples and patient VRE isolates indicated a role for contaminated surfaces in this cluster. Indirect contact has been frequently described as route of transmission for VRE in the hospital setting, due to the persistence of the bacterium [14, 22]. WGS in combination with epidemiological data analysis suggests that contaminated surfaces were also involved in ongoing transmission during this reported cluster. Analysis of the WGS data showed that the VRE isolates of patients in the COVID-19 isolation ward differed by 6 alleles to the isolates of SARS-CoV-2 negative patients. However, based on epidemiological data, it is difficult to draw conclusion if this represents two separate transmission events. The majority of clones identified during the cluster were MLST ST117 and vanB positive. These clones are known to cause nosocomial outbreaks and match the current VRE epidemiology in German hospitals [23]. Enhanced infection control bundles were effective in terminating the transmission chains. Intriguingly, this cluster started despite intensified contact precautions, including PPE and isolation of COVID-19 confirmed or suspected patients. Environmental sampling uncovered not only VRE, but also a variety of other nosocomial pathogens such as vancomycin susceptible enterococci, S. aureus, nonfermenters and Enterobacterales. This illustrates the importance of hand and surface disinfection within infection prevention bundles. At the time of the cluster, minimum staffing requirements in German hospitals have been suspended in order to cope with the ongoing COVID-19 pandemic. This situation is worrying as reduced personal is associated with poor adherence to infection control measures [24, 25]. Surveillance strategies will be important to elucidate any increase in hospital acquired infections and transmission events during this challenging situation. Infection control specialists need to raise awareness for long-established infection control routine measures as part of COVID-19 management in order to reduce mortality and morbidity associated with nosocomial infections.

Conclusions

Our observation constitutes initial evidence of a feared yet unassessed negative impact of resource diversion on the epidemiology of MDRO, highlighting the need for continued infection prevention and control measures during the time of the COVID-19 pandemic to prevent transmissions and healthcare associated infections with MDRO.
  23 in total

1.  Risk factors for vancomycin-resistant enterococci infection and mortality in colonized patients on intensive care unit admission.

Authors:  Youn Jeong Kim; Sang Il Kim; Yang Ree Kim; Ji Young Lee; Yeon Joon Park; Moon Won Kang
Journal:  Am J Infect Control       Date:  2012-04-06       Impact factor: 2.918

2.  Expansion of Vancomycin-Resistant Enterococcus faecium in an Academic Tertiary Hospital in Southwest Germany: a Large-Scale Whole-Genome-Based Outbreak Investigation.

Authors:  Jan Liese; Leonard Schüle; Philipp Oberhettinger; Leonie Tschörner; Tran Nguyen; Daniela Dörfel; Wichard Vogel; Matthias Marschal; Ingo Autenrieth; Matthias Willmann; Silke Peter
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

3.  The effect of workload on infection risk in critically ill patients.

Authors:  Stéphane Hugonnet; Jean-Claude Chevrolet; Didier Pittet
Journal:  Crit Care Med       Date:  2007-01       Impact factor: 7.598

Review 4.  VRE and VSE Bacteremia Outcomes in the Era of Effective VRE Therapy: A Systematic Review and Meta-analysis.

Authors:  Chatura Prematunge; Colin MacDougall; Jennie Johnstone; Kwaku Adomako; Freda Lam; Jennifer Robertson; Gary Garber
Journal:  Infect Control Hosp Epidemiol       Date:  2015-10-05       Impact factor: 3.254

5.  Empiric Antibacterial Therapy and Community-onset Bacterial Coinfection in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19): A Multi-hospital Cohort Study.

Authors:  Valerie M Vaughn; Tejal N Gandhi; Lindsay A Petty; Payal K Patel; Hallie C Prescott; Anurag N Malani; David Ratz; Elizabeth McLaughlin; Vineet Chopra; Scott A Flanders
Journal:  Clin Infect Dis       Date:  2021-05-18       Impact factor: 9.079

6.  Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results From the SENTRY Antimicrobial Surveillance Program, 1997-2016.

Authors:  Michael A Pfaller; Martin Cormican; Robert K Flamm; Rodrigo E Mendes; Ronald N Jones
Journal:  Open Forum Infect Dis       Date:  2019-03-15       Impact factor: 3.835

7.  Risk Factors for Long-Term Vancomycin-Resistant Enterococci Persistence-A Prospective Longitudinal Study.

Authors:  Carlos L Correa-Martinez; Verena B Stollenwerk; Annelene Kossow; Frieder Schaumburg; Alexander Mellmann; Stefanie Kampmeier
Journal:  Microorganisms       Date:  2019-09-26

8.  Transmission of Vancomycin-Resistant Enterococci in the Hospital Setting: Uncovering the Patient-Environment Interplay.

Authors:  Carlos L Correa-Martinez; Hauke Tönnies; Neele J Froböse; Alexander Mellmann; Stefanie Kampmeier
Journal:  Microorganisms       Date:  2020-01-31

9.  COVID-19 and the potential long-term impact on antimicrobial resistance.

Authors:  Timothy M Rawson; Luke S P Moore; Enrique Castro-Sanchez; Esmita Charani; Frances Davies; Giovanni Satta; Matthew J Ellington; Alison H Holmes
Journal:  J Antimicrob Chemother       Date:  2020-07-01       Impact factor: 5.790

10.  Indications for healthcare surge capacity in European countries facing an exponential increase in coronavirus disease (COVID-19) cases, March 2020.

Authors:  Frederik Verelst; Elise Kuylen; Philippe Beutels
Journal:  Euro Surveill       Date:  2020-04
View more
  21 in total

Review 1.  Application of Nanomaterials in the Prevention, Detection, and Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors:  John Hulme
Journal:  Pharmaceutics       Date:  2022-04-06       Impact factor: 6.525

2.  Long-Term Impact of the COVID-19 Pandemic on In-Hospital Antibiotic Consumption and Antibiotic Resistance: A Time Series Analysis (2015-2021).

Authors:  Marianna Meschiari; Lorenzo Onorato; Erica Bacca; Gabriella Orlando; Marianna Menozzi; Erica Franceschini; Andrea Bedini; Adriana Cervo; Antonella Santoro; Mario Sarti; Claudia Venturelli; Emanuela Biagioni; Irene Coloretti; Stefano Busani; Massimo Girardis; José-María Lòpez-Lozano; Cristina Mussini
Journal:  Antibiotics (Basel)       Date:  2022-06-20

3.  Development and Characterization of High-Throughput Caenorhabditis elegans - Enterococcus faecium Infection Model.

Authors:  Alexey V Revtovich; Elissa Tjahjono; Kavindra V Singh; Blake M Hanson; Barbara E Murray; Natalia V Kirienko
Journal:  Front Cell Infect Microbiol       Date:  2021-04-29       Impact factor: 5.293

4.  Care bundles for improving outcomes in patients with COVID-19 or related conditions in intensive care - a rapid scoping review.

Authors:  Valerie Smith; Declan Devane; Alistair Nichol; David Roche
Journal:  Cochrane Database Syst Rev       Date:  2020-12-21

5.  How the COVID-19 pandemic changed postoperative infections in urology wards: A retrospective cohort study from two urology departments.

Authors:  Bernardo L Teixeira; João Cabral; André Marques-Pinto; Fernando Vila; Joaquim Lindoro; Avelino Fraga
Journal:  Can Urol Assoc J       Date:  2022-05       Impact factor: 2.052

6.  Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance?

Authors:  Dominique L Monnet; Stephan Harbarth
Journal:  Euro Surveill       Date:  2020-11

7.  Antimicrobial TiO2 nanocomposite coatings for surfaces, dental and orthopaedic implants.

Authors:  Vignesh Kumaravel; Keerthi M Nair; Snehamol Mathew; John Bartlett; James E Kennedy; Hugh G Manning; Barry J Whelan; Nigel S Leyland; Suresh C Pillai
Journal:  Chem Eng J       Date:  2021-02-23       Impact factor: 13.273

Review 8.  Impact of SARS-CoV-2 Epidemic on Antimicrobial Resistance: A Literature Review.

Authors:  Francesco Vladimiro Segala; Davide Fiore Bavaro; Francesco Di Gennaro; Federica Salvati; Claudia Marotta; Annalisa Saracino; Rita Murri; Massimo Fantoni
Journal:  Viruses       Date:  2021-10-20       Impact factor: 5.048

9.  The Role of Whole Genome Sequencing in the Surveillance of Antimicrobial Resistant Enterococcus spp.: A Scoping Review.

Authors:  Lindsay A Rogers; Kayla Strong; Susan C Cork; Tim A McAllister; Karen Liljebjelke; Rahat Zaheer; Sylvia L Checkley
Journal:  Front Public Health       Date:  2021-06-10

10.  Impact of coronavirus disease 2019 on infectious disease treatment and infection control at a tertiary hospital in Japan.

Authors:  Waki Imoto; Koichi Yamada; Gaku Kuwabara; Wataru Shibata; Norihiro Sakurai; Yuka Nonose; Yasuyo Okada; Kiyotaka Nakaie; Akiko Fujita; Hiroshi Kakeya
Journal:  J Infect Chemother       Date:  2022-01-26       Impact factor: 2.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.